NCT02721459
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02721459 |
| Title | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | Yes |
| Sponsors | H. Lee Moffitt Cancer Center and Research Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
CKB BOOST